Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up

by Zacks Equity Research

Halozyme reports better-than-expected third-quarter 2024 results. The company raises revenue guidance for 2024. Stock rises in after-hours trading.

Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down

by Zacks Equity Research

ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.

Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View

by Zacks Equity Research

BIIB's Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.

AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View

by Zacks Equity Research

ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product sales for immunology drugs.

Kinjel Shah headshot

Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News

by Kinjel Shah

Roche announces third-quarter and nine-month results. Sanofi holds exclusive talks with CD&R to sell a 50% stake in Opella.

Sundeep Ganoria headshot

Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?

by Sundeep Ganoria

Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.

CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases

by Zacks Equity Research

Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.

Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024

by Zacks Equity Research

RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.

Mark Vickery headshot

Top Stock Reports for NVIDIA, Microsoft & Broadcom

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Microsoft Corporation (MSFT) and Broadcom Inc. (AVGO), as well as a micro-cap stocks Comstock Holding Companies, Inc. (CHCI).

The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi

by Zacks Equity Research

Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs

by Kinjel Shah

J&J tops third-quarter earnings and sales estimates. FDA approves new drugs of Pfizer, Roche and AbbVie.

JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study

by Zacks Equity Research

Data from a late-stage study showed that Jazz's Zepzelca, combined with Roche's Tecentriq, improved survival rates in certain patients with small-cell lung cancer.

Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting

by Zacks Equity Research

RHHBY obtains FDA approval for Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Regeneron Gains 13.5% Year to date: How to Play the Stock?

by Zacks Equity Research

REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.

ONCY Stock Up on Regulatory Update From Breast Cancer Program

by Zacks Equity Research

Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a breast cancer indication.

Here's Why You Should Add ALNY Stock to Your Portfolio Right Now

by Zacks Equity Research

Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.

Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors

by Zacks Equity Research

RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.

Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals

by Zacks Equity Research

RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for treating active lupus nephritis.

Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea

by Zacks Equity Research

A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.

Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion

by Zacks Equity Research

REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.

Roche Antiviral Drug Reduces Transmission in Late-stage Study

by Zacks Equity Research

Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?

by Zacks Equity Research

The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.

Sweta Killa headshot

Tap the Weight-Loss Drug Market With These ETFs

by Sweta Killa

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

RHHBY or ABBV: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

RHHBY vs. ABBV: Which Stock Is the Better Value Option?

Regeneron, SNY Win FDA Approval for a Broader Dupixent Label

by Zacks Equity Research

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.